Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19

Disease modifying therapies and Covid‐19 severity in Multiple Sclerosis

(2021) Maria Pia Sormani et al.   ANNALS OF NEUROLOGY

COVID‐19 vaccine‐readiness for anti‐CD20‐depleting therapy in autoimmune diseases

(2020) D. Baker et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

An Italian programme for COVID-19 infection in multiple sclerosis

(2020) Maria Pia Sormani   LANCET NEUROLOGY

Neurological immunotherapy in the era of COVID-19 — looking for consensus in the literature

(2020) Catharina Korsukewitz et al.   Nature Reviews Neurology

Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study

(2020) Amit Bar-Or et al.   NEUROLOGY

Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis

(2020) Céline Louapre et al.   JAMA Neurology

Favorable outcome after COVID-19 infection in a multiple sclerosis patient initiated on ocrelizumab during the pandemic

(2020) Mahsa Ghajarzadeh et al.   Multiple Sclerosis and Related Disorders

Anti-CD20 and COVID-19 in multiple sclerosis and related disorders: A case series of 60 patients from Madrid, Spain

(2020) Paloma Montero-Escribano et al.   Multiple Sclerosis and Related Disorders

Merits and culprits of immunotherapies for neurological diseases in times of COVID-19

(2020) Marc Pawlitzki et al.   EBioMedicine

Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond?

(2020) Adil Maarouf et al.   Neurology-Neuroimmunology & Neuroinflammation

The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosis.

(2020) David Baker et al.   Multiple Sclerosis and Related Disorders

Mild clinical manifestations of SARS-CoV-2 related pneumonia in two patients with multiple sclerosis under treatment with ocrelizumab

(2020) Marco Iannetta et al.   Multiple Sclerosis and Related Disorders

COVID‐19 in multiple sclerosis patients: susceptibility, severity risk factors and serological response

(2020) Ana Zabalza et al.   EUROPEAN JOURNAL OF NEUROLOGY

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

(2020) Fernando P. Polack et al.   NEW ENGLAND JOURNAL OF MEDICINE

Experience in Multiple Sclerosis Patients with COVID-19 and Disease-Modifying Therapies: A Review of 873 Published Cases

(2020) Nora Möhn et al.   Journal of Clinical Medicine

Influence of delaying ocrelizumab dosing in multiple sclerosis due to COVID-19 pandemics on clinical and laboratory effectiveness

(2020) Barbara Barun et al.   Multiple Sclerosis and Related Disorders

COVID-19 in ocrelizumab-treated people with multiple sclerosis

(2020) Richard Hughes et al.   Multiple Sclerosis and Related Disorders

CD20 monoclonal antibodies for the treatment of multiple sclerosis: up-to-date

(2019) Mihai Ancau et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Age and the risks of high-efficacy disease modifying drugs in multiple sclerosis

(2019) Finja Schweitzer et al.   CURRENT OPINION IN NEUROLOGY

Immune reconstitution therapies: concepts for durable remission in multiple sclerosis

(2019) Jan D. Lünemann et al.   Nature Reviews Neurology

Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies

(2019) Gustavo Luna et al.   JAMA Neurology

Functional characterization of reappearing B cells after anti-CD20 treatment of CNS autoimmune disease

(2018) Darius Häusler et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Peripheral CD19+ B-cell counts and infusion intervals as a surrogate for long-term B-cell depleting therapy in multiple sclerosis and neuromyelitis optica/neuromyelitis optica spectrum disorders

(2018) Gisa Ellrichmann et al.   JOURNAL OF NEUROLOGY

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

(2017) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE

Extended interval dosing of natalizumab in multiple sclerosis

(2016) L Zhovtis Ryerson et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Targeting B cells in relapsing–remitting multiple sclerosis: from pathophysiology to optimal clinical management

(2016) Stefan Bittner et al.   Therapeutic Advances in Neurological Disorders

The effect of rituximab on vaccine responses in patients with immune thrombocytopenia

(2013) I. Nazi et al.   BLOOD

Reduced antibody formation after influenza vaccination in patients with neuromyelitis optica spectrum disorder treated with rituximab

(2013) W. Kim et al.   EUROPEAN JOURNAL OF NEUROLOGY

A 5-Year Follow-up of Rituximab Treatment in Patients With Neuromyelitis Optica Spectrum Disorder

(2013) Su-Hyun Kim et al.   JAMA Neurology

Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab

(2011) H. L. Pellkofer et al.   NEUROLOGY